Evidence map›Paper›PMID 42027240›Full record

ArticleUrology case reports2026

A case of renal primary neuroendocrine tumor (G3) in which 177Lu-PRRT was effective for disease control.

Saki Inaba, Toshiki Kijima, Mina Takaoka, Toshitaka Uematsu, Kohei Takei, Masahiro Yashi, Kazuyuki Ishida, Taku Aoki, Takao Kamai

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saki InabaDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Toshiki KijimaDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Mina TakaokaDepartment of Diagnostic Pathology, Dokkyo Medical University, Tochigi, Japan.
Toshitaka UematsuDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Kohei TakeiDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Masahiro YashiDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.
Kazuyuki IshidaDepartment of Diagnostic Pathology, Dokkyo Medical University, Tochigi, Japan.
Taku AokiDepartment of Hepato-Biliary-Pancreatic Surgery, Dokkyo Medical University, Tochigi, Japan.
Takao KamaiDepartment of Urology, Dokkyo Medical University, Tochigi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary renal neuroendocrine tumor (NET) is extremely rare, with no established treatment for advanced cases. We report high-grade (G3) renal NET effectively treated with peptide receptor radionuclide therapy (PRRT). A 30-year-old man was diagnosed with primary renal NET G3 with liver metastases. After everolimus failure, he received 177Lu-DOTATATE (Lutathera®). Although the tumor continued growing after the first cycle, disease stabilized from the second cycle onwards. Stable disease was maintained for 12 months without severe adverse events, preserving quality of life. 177Lu-PRRT is a promising therapeutic option for high-grade, somatostatin receptor-positive renal NET when other treatments fail.

Indexed as

177Lu-DOTATATEKidneyNeuroendocrine tumorPeptide receptor radionuclide therapy (PRRT)

Identifiers

PMID42027240
PMCPMC13100481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.